Biotech entity
Abbott Laboratories is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. That works out to roughly 0.1 stories per week across a 151-day span. Each story carries 2 original sources on average, compared with 3.8 for the broader beat in this window.
Last mentioned: Aug 5, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Abbott Laboratories is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. That works out to roughly 0.1 stories per week across a 151-day span. Each story carries 2 original sources on average, compared with 3.8 for the broader beat in this window. At 6, the average consequence score sits below the same-window beat average of 6.2. The clearest coverage concentration is clinical-trial: 1 of 2 stories, with the rest divided among 1 other category. We currently track 2 Biotech stories that mention BPL-003, published between March 8, 2026 and August 5, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 493 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering BPL-003. Shared-story counts are live from our verified record — not editorial picks.
Enrollment Milestone
Estimated completion of patient enrollment for the global Phase 3 study.
Phase 3 Launch Window
Expected start of the pivotal Phase 3 trial for Treatment-Resistant Depression.
Earnings & Timeline Release
Company announces 2025 results and sets Q2 2026 for BPL-003 Phase 3 launch.
FY 2025 Close
End of the fiscal year reporting period for AtaiBeckley.
CareDx surged 35% after Medicare finalized coverage for transplant rejection tests, unlocking a major revenue opportunity. AtaiBeckley soared 33% following Eli Lilly's $3.8B acquisition, while Abbott raised its outlook and Apollomics extended its weekly rally to over 60% on its cancer drug candidate.
Source: rttnews.com · finanznachrichten.de
AtaiBeckley (ATAI) has confirmed the Q2 2026 launch of its Phase 3 program for BPL-003, an intranasal 5-MeO-DMT formulation for Treatment-Resistant Depression. The announcement follows the release of 2025 financial results that show a robust cash position capable of funding pivotal late-stage clinical development.
BPL-003 is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
